Improving the lives of every patient, every day is the mission that drives the people of Fresenius Medical Care North America. As a premier vertically integrated healthcare company, we are leaders in value-based care by embracing innovation across our network of dialysis facilities, outpatient cardiac and vascular labs, urgent care centers, specialty pharmacy and laboratory services and insurance companies. Our employees, physicians and caregivers across the continent are connected through one uniting purpose: the patients who entrust us with their care.

This is an exciting time in nephrology with new innovations and

insights offering promise for the advancement of kidney care.

We hope you’ll experience the different businesses, researchers

and clinical experts Fresenius Medical Care is proud to feature at

this year’s conference.

From scientific research to advanced equipment, products and

services, our diverse range of offerings at this year’s symposium

includes clinical research for advancing new drugs and devices;

electronic medical record solutions; home and in-center dialysis

products; pharmaceuticals; laboratory analysis and reporting;

and more connected and personalized dialysis services. We also

present 71 abstracts in oral talks, poster presentations, and

publications featuring the work of our Fresenius Medical

Care-affiliated researchers, clinicians and caregivers across

the globe.

Fresenius Medical Care is committed to translating science

into practice and embraces innovation across our network of

dialysis facilities, outpatient cardiac and vascular labs, urgent

care centers, specialty pharmacy and laboratory services.

We appreciate the opportunity to share insights on our global

work to improve the lives of every patient, every day. Thank you

for your interest in our company.

Frank W. Maddux, MD, FACP

Chief Medical Officer

Executive Vice President for Clinical and Scientific Affairs

Fresenius Medical Care North America

Welcome to ASN Kidney Week 2018

ASN Kidney Week 2018October 23 - 28, 2018 | San Diego, CA

MEET OUR EXHIBITORSThe following Fresenius Medical Care North America business units are featured at

this year’s symposium:

ACUMEN PHYSICIAN SOLUTIONS

Booth 2220 Franklin, Tennessee-based Acumen Physician Solutions develops and delivers intuitive software tools to assist nephrologists in the practice of medicine. Our nephrology-specific products include: Acumen 2.0 Powered by Epic, Acumen Revenue Cycle Management, Acumen Mobile Charge Capture, Acumen Nephrologixx, and Acumen PQRS.

FRENOVA RENAL RESEARCH

Booth 2229 Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research. As a Fresenius Medical Care North America company, Frenova manages a networked system of clinical research assets and resources including over 450 principal

investigators at more than 260 sites, representing 160 medical practices and nearly 700 dialysis clinics. Frenova manages clinical trials in kidney disease and its adjacent medical conditions. When you need to conduct a complete renal clinical program, trust the partner that’s completely renal.

FRESENIUS KIDNEY CARE

Booth 1913 Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and services to more than 190,000 patients with kidney disease at more than 2,200 facilities nationwide. Fresenius Kidney Care supports people by helping to address both the physical and emotional aspects of kidney disease through personalized care, education and lifestyle support services so they can lead meaningful and fulfilling lives.

Communities Lounge

#1903 Fresenius Medical Care —

Renal Therapies Group

#2410 Renal Research Inst.

#2418 Spectra Laboratories

#1913 Fresenius Kidney Care

#2220 Acumen Physician Solutions

#2229 Frenova Renal Research

FRESENIUS MEDICAL CARE — RENAL THERAPIES GROUP

Booth 1903 Through two divisions — Renal Technologies and Renal Pharmaceuticals — Fresenius Medical Care North America (FMCNA) provides hemodialysis and peritoneal dialysis equipment, as well as renal pharmaceuticals, in support of clinical and home environments.

RENAL RESEARCH INSTITUTE

Booth 2410 RRI is a unique research organization that stands at the forefront of medical research in chronic kidney disease, particularly in patients undergoing renal replacement therapies. It has been a leading force behind landmark studies on hemodialysis, and has a solid and successful partnership with national and international academic institutions. Its research spans a full spectrum of interests from molecular biology and clinical research to epidemiology. RRI hosts a distinguished annual International Conference on Dialysis and trains research fellows from more than 30 countries around the world.

SPECTRA LABORATORIES

Booth 2418 Spectra delivers renal-specific testing, analysis and reporting with the reliability you require to ensure the best outcomes possible for your patients. Our team of clinical experts, paired with our patient-centric tools and resources, help you comply with industry guidelines.

Our scientific efforts to enhance quality of life and patient outcomes fall into seven general categories:

1. Advancing technologies in home and

in-center therapies

2. Using mathematical modeling and

artificial intelligence to improve care

paradigms

3. Understanding dialysis patient

satisfaction and outcomes

4. Driving advancements in treatments for

mineral bone disorders and anemia

5. Spearheading research in

underrepresented populations with

renal diseases

6. Identifying determinants of patient

kinetics and self-reported outcomes

FRESENIUS MEDICAL CARE PRESENTATIONSThe following presentations by Fresenius Medical Care-affiliated researchers and caregivers are

featured at this year’s symposium. Authors will be presenting their work and are available for

questions during the presentation dates and times noted below.

THURSDAY, OCTOBER 25, 2018

Effect of Hemodiafiltration (HDFIT) on Physical Activity and Self-Reported Outcomes: Primary Results of the Brazilian HDFIT Trial. Late-Breaking Clinical Trial Presentation

Roberto Pecoits-Filho, John W. Larkin, Priscila B. Gonçalves, Shimul Sheth, Hao Han, Carlos E. Poli de Figueiredo, Americo L. Cuvello Neto, Ana Beatriz L. Barra, Jochen G. Raimann, Maria Eugenia F. Canziani, On behalf of the HDFIT Study Investigators

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO1169]

International Comparisons of Mortality Among Hemodialysis Patients in the DOPPS*

Keith McCullough, Eric W. Young, Steven M Brunelli, Daniel E. Weiner, John Hartman, Dino B Capone, Bruce M Robinson

[4:42 p.m. – 4:54 p.m. | Room 2 | TH-OR092]

Changes in Serum Phosphorus (sP) Among Patients with Hyperphosphatemia (sP >5.5 mg/dL) Switched to Sucroferric Oxyhydroxide for Two Years

Stuart M. Sprague, Vidhya Parameswaran, Linda Ficociello, Claudy Mullon, Robert J. Kossman

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO195]

Serum Phosphorus (sP) Lowering Effect of Sucroferric Oxyhydroxide (SO) in Phosphate-Binder (PB) Naïve Hemodialysis Patients (pts) over 12 Months

Kamyar Kalantar-Zadeh, Linda Ficociello, Vidhya Parameswaran, Claudy Mullon, Robert J. Kossman, Stuart Sprague

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO196]

Serum Phosphorus and Phosphate Binder (PB) Pills/Day Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide (SO) for a Year Compared to Patients Who Discontinue SO and Are Prescribed Other PB

Daniel W. Coyne, Linda Ficcociello, Vidhya Parameswaran, Claudy Mullon, Robert J. Kossman

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO197]

Effectiveness of Sucroferric Oxyhydroxide in Phosphate Binder-Naïve and Experienced Patients: A Real-World Retrospective Database Analysis

Charles Chazot, Rosa Ramos, Attilio Di Benedetto, Manuel A. Ferreira, Birgit Kagermeier, Hans-Juergen Arens, Sebastian Walpen, Viatcheslav Rakov, Stefano Stuard

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO201]

Using Machine Learning to Help Predict Elevated Serum Phosphate Levels in Patients with ESRD

Andrew Long, Tommy C. Blanchard, Joanna Willetts, Sheetal Chaudhuri, Michael R. O’Connell, Kathleen Belmonte, Marissa A. Lee, Len A. Usvyat, Terry L. Ketchersid, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO203]

Hypoparathyroidism and Malnutrition – Two Sides of the Same Coin?

Peter Taborsky, Lidmila Francova, Ivan Rychlik

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO218]

Effects of Dosing Frequency on the Efficiency of EPO Administration in Hemodialysis Patients

Sabrina Rogg, Doris H. Fuertinger, Stefan Volkwein, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO229]

Real-World Experience with C.E.R.A. in Pediatric Dialysis Patients Fit Modeling-Based Predictions: Results from the IPDN Registries*

Franz S. Schaefer, Pascal Chanu, Laura Benner, Nicolas Frey, Hui Kim Yap, Karel Vondrak, Paula A. Coccia, IL-Soo Ha, Rainer Büscher, Heiko Billing, Claus Peter Schmitt, Charlotte Samaille, Bradley A. Warady

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO233]

* Denotes presentations supported by Fresenius Medical Care

The Impact of Newly Developed Inflammation, Characterized by the Rise in C-Reactive Protein, on Anemia Management Practices in Hemodialysis Patients: A Before-After Design in the DOPPS* Angelo Karaboyas, Hal Morgenstern, Raymond C. Vanholder, Nancy L. Fleischer, Douglas E. Schaubel, Elke Schaeffner, Tadao Akizawa, Nafeesa N. Dhalwani, Marvin Sinsakul, Ronald L. Pisoni, Bruce M. Robinson

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO252]

Estimation of Pre-Dialysis Hemoglobin Concentration Using Intradialytic Crit-Line Monitor Readings

Ohnmar Thwin, Priscilla Preciado, Xia Tao, Samir D. Patel, Mirell Tapia, Lemuel Rivera, Stephan Thijssen, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO259]

Associations of Anemia with Quality of Life in CKD Stage 3-5 Patients: Results from CKDopps in the US and Brazil*

Nidhi Sukul, Daniel G. Muenz, Elodie Speyer, Antonio A. Lopes, Koichi Asahi, Junichi Hoshino, Nafeesa N. Dhalwani, Heleen van Haalen, Roberto Pecoits-Filho, Brian Bieber, Bruce M. Robinson, Ronald L. Pisoni

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO266]

Do Better Medical Results Mean Higher Costs for the Dialysis Clinic?

Wojciech Marcinkowski, Jacek P. Zawierucha, Jolanta Malyszko, Jacek S. Malyszko

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO278]

Estimated Revenue Gains Associated with Relative Blood Volume Monitoring (RBV-M) in Hemodialysis (HD) Clinics: An Economic Model Using Real-World Data and a Case Size of 12 Medicare Incident Patients

Melissa M. Rosen, Yisha Li, Linda. Ficociello, Paul Balter, Claudy Mullon, Robert J. Kossman, Gary G. Singer

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO284]

Sex- and Age-Associated Differences in the Prevalence of Comorbidities in Dialysis Patients

Sophia Rosen, Dugan Maddux, John W. Larkin, Len A. Usvyat, Franklin W. Maddux, Marta Reviriego-Mendoza

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO291]

Gender-Specific Differences Associated with Sociocultural Attributes in Dialysis Patients: A National Cohort Analysis

Sophia Rosen, Maria E. Ferris, Nwamaka D. Eneanya, Carly R. Van Zandt, Priscila Preciado, John W. Larkin, Len A. Usvyat, Franklin W. Maddux, Dugan Maddux, Marta Reviriego-Mendoza

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO292]

Are Hemoglobin Levels Affected by Sex, Age, and Race in Dialysis Patients?

Marta Reviriego-Mendoza, Sophia Rosen, Dugan Maddux, John W. Larkin, Len A. Usvyat, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO293]

Allo-Hemodialysis: Intermittent Donation of Kidney Function as a Novel Treatment for Patients with Kidney Failure in Limited Resource Settings

Peter Kotanko, Vaibhav Maheshwari, Stephan Thijssen

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO342]

Regional Variation in Peritoneal Dialysis (PD) Time on Therapy (ToT): Results from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)*

Jeffrey Perl, Junhui Zhao, Bruce M. Robinson, Simon J. Davies, Hideki Kawanishi, David W. Johnson, James A. Sloand, Mauricio Sanabria, Talerngsak Kanjanabuch, Yong-Lim Kim, Jenny I. Shen, Ronald L. Pisoni

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO371]

Smartphone-Based Point-of-Care Diagnostics for Early Detection of Peritonitis

Nadja Grobe, Xia Tao, Mia G. Garbaccio, Maricar Villarama, Christopher Hanrahan, Stephan Thijssen, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO397]

Educational Symposia Sponsored by Fresenius Medical Care Renal Therapies Group

Thursday, October 25, 2018

Volume Management in Hemodialysis Patients: From Art to Science [12:45 p.m.-1:45 p.m.; Marriot Marquis San Diego Marina, North Tower Pacific Ballroom, Salon 21]

Friday, October 26, 2018

Diet and Lifestyle with CKD: Focus on Phosphorus [12:45 p.m.-1:45 p.m.; Marriot Marquis San Diego Marina, North Tower Pacific Ballroom, Salon 21]

A Machine Learning Model to Predict Patient Risk of Peritonitis Episodes

Tommy C. Blanchard, Joanna Willetts, Michael R. O’Connell, Sheetal Chaudhuri, Len A. Usvyat, Brian C. Ellison, Judith Moran, Melissa Herman, Susan M. Dunphy, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO408]

Clinical Features of Dialysis Patients at Risk of Lower Limb Amputation

Karen G. Butler, Michael R. O’Connell, Sheetal Chaudhuri, Hao Han, Marta Reviriego-Mendoza, Dugan Maddux, John W. Larkin, Len A. Usvyat, Terry L. Ketchersid, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO453]

Urinary MicroRNAs in Fabry Disease Patients with Mild Nephropathy

Sebastian P. Jaurretche, Graciela Venera, Norberto Ricardo Antongiovanni, Fernando J. Perretta, German Perez

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO732]

The Relationship Between Body Mass Index (BMI) and Outcomes in Health and CKD

Jochen G. Raimann, Peter Kotanko, Levi D. Waldron

[10 a.m. – 12 p.m. | Exhibit Hall | TH-PO1101]

FRIDAY, OCTOBER 26, 2018

Effects of a Comprehensive Volume Reduction Protocol on Hydration Status and Blood Pressure Control in Hemodialysis Patients*

Ken Wilund, Luis M. Perez, Brett Burrows, Alana P. Harris, Jennifer L. Barnes, Lauren Chan

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO356]

Hypoxia Increases Erythrocyte Death Rate and Oxidative Stress Induced by Indoxyl Sulfate

Andrea Moreno-Amaral, Gabriela F. Dias, Sara S. Tozoni, Natalia Borges Bonan, Roberto Pecotis-Filho, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO476]

In Silico Model of PTH-Induced Self-Limiting Anti-Apoptotic Signaling Pathways in Osteoblasts

Alhaji Cherif, Doris H. Fuertinger, Stephan Thijssen, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO511]

Profiles of Physical Activity in Hemodialysis Patients Randomized into the HDFIT Trial

John W. Larkin, Priscila B. Gonçalves, Hao Han, Jochen G. Raimann, Maggie Han, Carlos E. Poli de Figueiredo, Americo L. Cuvello Neto, Ana Beatriz L. Barra, Len A. Usvyat, Peter Kotanko, Maria Eugenia F. Canziani, Roberto Pecoits-Filho, On Behalf of the HDFIT Study Investigators

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO536]

Relationships Between Satisfaction Scores and Outcomes in Dialysis Patients

Yue Jiao, John W. Larkin, Marta Reviriego-Mendoza, Amy Barry, Judy L. Green, Len A. Usvyat, Jeffrey L. Hymes, Angela McClure, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO567]

Hospital Admission Rates Are Associated with Depressive Affect and Antidepressant Use in Dialysis Patients

Billy Kim, Marissa A. Lee, Sheetal Chaudhuri, Hao Han, Marta Reviriego-Mendoza, John W. Larkin, Len A. Usvyat, Terry L. Ketchersid, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO569]

Associations Between Use of a Patient Portal with Hospitalization Rates and Modality Failure in Peritoneal Dialysis Patients

Carlos Muchiutti, Bryan Fore, Sheetal Chaudhuri, Sophia Rosen, Hao Han, Marta Reviriego-Mendoza, John W. Larkin, Len A. Usvyat, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO686]

Calcium Mass Balance During Hemodialysis: A Comparison of Different Dialysate Calcium Concentrations Including Citrate-Acid Calcified Dialysate

Karlien J. ter Meulen, Frank van der Sande, Constantijn Konings, Marijke J. Dekker, Bernard J. Canaud, Jeroen Kooman

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO746]

Reduction in Mean Patient Body Weights and Blood Pressures Were Observed During a Fluid Management Quality Improvement (QI) Project Utilizing Relative Blood Volume Monitoring (RBV-M)

Paul Balter, Yisha Li, Claudy Mullon, Robert J. Kossman, Linda Ficociello

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO747]

Screening for Obstructive Sleep Apnea in Hemodialysis Patients Using the Crit-Line Monitor

Ohnmar Thwin, Xia Tao, Mirell Tapia, Priscila Preciado, Stephan Thijssen, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO753]

Determination of Calf Normalized Resistivity at 50 kHz in the General Population

Fansan Zhu, Samer R. Abbas, Laura Rosales, Nathan W. Levin, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO754]

Safety and Effectiveness of Sucroferric Oxyhydroxide in Dialysis Patients: 24-Month Interim Analysis of the VERIFIE Study

Markus Ketteler, John Boletis, Angel Luis M. De Francisco, Marc G.Vervloet, Philip A. Kalra, Denis Fouque, Piergiorgio Messa, Manuela Stauss-Grabo, Anja Derlet, Viatcheslav Rakov, Sebastian Walpen, Linda Ficociello, Jacques B. Rottembourg, Christoph Wanner, Jorge B. Cannata-Andia

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO763]

Neutrophils to Lymphocytes Ratio Prior to Death in Hemodialysis Patients: Results from the Global MONDO Initiative

Xiaoling Ye, Dalia E. Yousif, Jochen G. Raimann, Yuedong Wang, Jeroen Kooman, Frank van der Sande, Stefano Stuard, Bernard J Canaud, Adrian M. Guinsburg,

Len A. Usvyat, Peter Kotanko, The MONDO Initiative

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO768]

HCV in Hemodialysis Patients: Where Is the Difference?

Adrian M. Guinsburg, Marcelo D. Ferder

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO772]

Lower Rates of Hospital Admissions During a Fluid Management Quality Improvement (QI) Project Utilizing Relative Blood Volume Monitoring (RBV-M) -A Retrospective Database Analysis

Paul Balter, Panduranga S. Rao, Yishi Li, Claudy Mullon, Robert J. Kossman, Linda Ficociello

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO788]

Using Artificial Intelligence to Help Predict Imminent Hospitalizations in Patients with ESRD

Andrew Long, Tommy C. Blanchard, Joanna Willetts, Hao Han, Michael R. O’Connell, Amanda K. Ward, Lisa Reighter, Scott Braverman, Kendra N. Smith, Annette L. Baker, Gamaela D. Brown, Greg S. Garza, Cara Gallagher, Jodi Conti, Sheetal Chaudhuri, Len A. Usvyat, Terry L. Ketchersid, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO791]

Estimating the Fraction of First-Year Hemodialysis Deaths Attributable to Potentially Modifiable Risk Factors: Results from the DOPPS*

Bruce M. Robinson, Hal Morgenstern, Angelo Karaboyas, Yun Li, Brian Bieber, Raymond M. Hakim, Takeshi Hasegawa, Michel Y. Jadoul, Elke Schaeffner, Raymond C. Vanholder, Ronald L. Pisoni, Friedrich K. Port

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO801]

Variability of Pre-Dialysis Serum Sodium, a Risk Factor of Survival in Hemodialysis Patients: Results from the Global MONDO Initiative

Xiaoling Ye, Jeroen Kooman, Frank van der Sande, Bernard J. Canaud, Stefano Stuard, Michael Etter, Xiaoqi Xu, Adrian M. Guinsburg, Len A. Usvyat, Yeudong Wang, Albert J. Power, Peter Kotanko, Jochen G. Raimann, The MONDO Initiative

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO804]

Effects of the Specific Oriented Care in Hemodialysis Incident Patients (SOCHIP) Program on Key Performance Indicators and Early Mortality

Charles Chazot, Stefano Stuard

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO806]

All-Cause Mortality in Relation to Intradialytic Relative Blood Volume and Central-Venous Oxygen Saturation Among Hemodialysis Patients

Hanjie Zhang, Priscilla Preciado, Lili chan, Stephan Thijssen, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO813]

Association Between Reduction of Extracellular Volume by In-Center Short Daily Hemodialysis and Survival

Ana Beatriz L. Barra, Ana P. Silva, Eufronio D’almeida, Marcos Sandro F. Vasconcelos, Jorge P. Strogoff-de-Matos

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO814]

Intradialytic Relative Blood Volume Changes and All-Cause Mortality Among Hemodialysis PatientsPriscila Preciado, Hanjie Zhang, Stephan Thijssen, Jeroen Kooman, Frank van der Sande, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO817]

Beta-2 Microglobulin Levels and All-Cause Mortality: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)*

Jeffrey Perl, Daniel G. Muenz, Brian Bieber, Aleix Cases, Elichiro Kanda, Francesco Locatelli, Hal Morgenstern, Friedrich K. Port, Bruce M. Robinson

[10 a.m. – 12 p.m. | Exhibit Hall | FR-PO825]

SATURDAY, OCTOBER 27, 2018

Thirst, Xerostomia, and Inter-Dialytic Weight Gain in the Sodium Lowering in Dialysate (SoLiD) Trail*

Brenda M Luey, Joanna L. Dunlop, Mark R Marshall, for the SoLID trial investigators

[4:42 p.m. – 4:54 p.m. | Room 2 | SA-OR069]

Bioelectrical Impedance Analysis (BIA) Versus Clinical Criteria for Setting Ultrafiltration (UF) in Chronic Hemodialysis (HD) Patients*

Jeffrey P Mora, Romina A. Danguilan, Concesa Casasola

[5:06 p.m. – 5:18 p.m. | Room 2 | SA-OR071]

Bone Loss in Kidney Transplant Recipients and Patients on Dialysis Treated with Nocturnal Hemodialysis, Conventional Hemodialysis, and Peritoneal Dialysis*

Thijs T. Jansz, Hanna C. Willems, Pim A. De Jong, Marianne C. Verhaar, Brigit C. van Jaarsveld

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO665]

Time-Integrated Fluid Load (TIFL) Predicts Left Ventricular Mass (LVM) Reduction: Results from the Frequent Hemodialysis Network (FHN) Daily Trial

Jochen G. Raimann, Christopher T. Chan, John T. Daugirdas, Thomas A. Depner, Brett Larive, Gerald J. Beck, Tom Greene, George A. Kaysen, Alan S. Kliger, Peter Kotanko, Robert M. Lindsay, Michael V. Rocco, Nathan W. Levin

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO874]

Agreement Between Spectra Hemoglobin and Crit-Line® Monitor Estimated Hemoglobin

Mirell Tapia, Hanjie Zhang, Xia Tao, Stephan Thijssen, Peter Kotanko

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO876]

Global Trends of Stroke in Haemodialysis (2000-2012): A Retrospective Cohort Study of the Monitoring Dialysis Outcomes Initiative

Albert Power, Xiaoling Ye, Len A. Usvyat, Stefano Stuard, Jochen G. Raimann, Adrian M. Guinsburg, Bernard J. Canuad, Xiaoqi Xu, Michael Etter, Jeroen Kooman, Frank van der Sande, Neill D. Duncan, Charles D. Pusey, Peter Kotanko, The MONDO Initiative

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO912]

Transcriptomic Analysis of PCK Rat Peritoneum After Long-Term Infusion of Dialysate with Mono or Dual* Therapy of a JAK1/2 Inhibitor and/or Losartan

Sonny T. Nguyen, Sharon G. Adler, Kana N. Miyata, Pei Zhang, Janine A. Lapage, Tiane Dai

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO930]

Is Abdominal Muscle the Right Parietal Peritoneal Tissue for Gene Expression Analysis?*

Pei Zhang, Kana N. Miyata, Sharon G. Adler, Cynthia C. Nast, Hashim Mapara, Janine A. La page, Tiane Dai

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO945]

Predictors of Complications During Outpatient Dialysis Access Procedures

Gregg Miller, Elsie Koh, Yue Jiao, Sophia Rosen, Marta Reviriego-Mendoza, John W. Larkin, Len A. Usvyat, Nancy Mclaughlin, Catherina Madormo, Murat Sor, Franklin W. Maddux

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO958]

Cardiac Structure in Patients with Mild to Moderate CKD – an MRI Study*

Markus P. Schneider, Johannes B. Scheppach, Thorsten Klink, Christoph Wanner, Georg Schlieper, Turgay Saritas, Jürgen Floege, Roland E. Schmieder, Kai-Uwe Eckardt

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO991]

Impact of Dialysis Treatment Shift on Malnutrition Indicators

Juan J. Carrero, Adam M. Zawada, Katharina Brand, Stefano Stuard, Bernard J. Canaud, Adelheid Gauly, Anke Winter, Denis Fouque

[10 a.m. – 12 p.m. | Exhibit Hall | SA-PO1060]

SUNDAY, OCTOBER 28, 2018

Unsung Heroes: Working with Family and Informal Caregivers

Felicia N. Speed

[10:30 – 11 a.m. | Room 6F]

BILL VALLE

Chief Executive Officer, Fresenius Medical Care North America

As Chief Executive Officer, Bill leads 12 vertically integrated

North American business units focused on products, services

and risk for renal disease and other chronic conditions. He

also sits on the Management Board of Fresenius Medical Care.

Previously, he was President of Fresenius Kidney Care, where he

was responsible for the successful management of more than

2,200 outpatient facilities, 1,400 inpatient programs and 800

home dialysis programs across the U.S. Prior to that, Bill served

as President of the company’s Integrated Renal Services, where

he led the transformation into a high performance renal network

to improve the outcomes and reduce the costs of managing

renal disease. Before joining the company, Bill had 22 years of

experience in the dialysis industry, serving in executive roles

in sales, marketing and business development and as owner of

several private dialysis centers.

MARK COSTANZO

President, Fresenius Medical Care Renal Therapies Group

As President, Fresenius Medical Care Renal Therapies Group,

Mark oversees renal products and pharmaceutical operations

including sales, marketing, the Renal Research Institute, medical

and regulatory affairs, as well as Mexico and Canada operations.

He assumed this position in January 2010. Mark joined

Fresenius Medical Care in 1990 and has held several positions

of increasing responsibility including Vice President, Peritoneal

Dialysis Products and Vice President, Sales and Marketing. He

began his career in the renal industry more than 30 years ago

with Baxter International.

MIKE ASSELTA

President, Fresenius Kidney Care, Executive Vice President, Fresenius Medical Care North America

As Executive Vice President of Fresenius Medical Care North

America and President of Fresenius Kidney Care, Mike is responsible

for overseeing our dialysis services business. In addition, he

leads the Operational Excellence team – including the Project

Management Office and the Information Security team – as well

as Spectra Laboratories. Prior to joining the company in 2015,

Mike had 20 years of experience in the healthcare industry,

including serving as Chief Operating Officer for LabOne, Inc., Vice

President for Quest Diagnostics and Executive Vice President

for SelectQuote Senior. Additionally, Mike served in an advisory

capacity to healthcare venture capital firms and on the boards

of several private companies. Mike earned a Master of Business

Administration from Baker University and completed Fresenius

Medical Care’s executive development program through Harvard

Business School.

FRANK MADDUX, MD, FACP

Chief Medical Officer and Executive Vice President, Clinical and Scientific Affairs, Fresenius Medical Care North America

As Chief Medical Officer and Executive Vice President for Clinical

and Scientific Affairs, Dr. Maddux is responsible for the delivery

of high quality, value-based care for the largest integrated renal

care network on the continent. Physician, IT entrepreneur and

healthcare executive, he has more than 30 years of healthcare

experience, including the practice of nephrology at the Danville

(Virginia) Urologic Clinic, where he served as its president from

1995 to 2005. Frank is a Clinical Associate Professor of Medicine

at the University of North Carolina School of Medicine and has

served on numerous boards and regional committees involved ➤

Meet Our Experts Thought Leaders at ASN Kidney Week 2018

in technology initiatives, banking and healthcare. He received

a bachelor’s degree in mathematics from Vanderbilt University

and his M.D. from the University of North Carolina at Chapel Hill,

where he completed his internship, residency, chief residency and

nephrology fellowship.

JEFFREY HYMES, MD

Senior Vice President and Chief Medical Officer, Fresenius Kidney Care

Dr. Jeffrey Hymes is Senior Vice President, Chief Medical

Officer for Fresenius Kidney Care and Chairman of its Pharmacy

and Therapeutics Committee. Dr. Hymes is a graduate of Yale

College and the Albert Einstein College of Medicine. He served

his medical internship and residency at Yale New Haven Medical

Center and received subspecialty training in nephrology at

Boston University. Dr. Hymes is board certified in internal

medicine, nephrology and critical care. He was a co-founder of

REN Corporation in 1986 and National Nephrology Associates

(NNA) in 1998. Dr. Hymes served as NNA’s President and Chief

Medical Officer from 1998 to 2004. From 1989 to 2012, he was

President of Nephrology Associates, a 32-physician nephrology

practice serving Tennessee, and is a former member of the

Renal Physician Association’s Board of Directors.

ROBERT KOSSMANN, MD, FACP, FASN

Senior Vice President and Chief Medical Officer, Fresenius Medical Care Renal Therapies Group

Dr. Robert Kossmann is Senior Vice President and Chief Medical

Officer for Fresenius Medical Care’s Renal Therapies Group,

the company’s medical equipment and renal pharmaceuticals

division. Dr. Kossmann practiced nephrology for two decades

prior to joining Fresenius Medical Care in 2014, and is the

former president of the Renal Physicians Association (RPA) and

a founding member of RPA’s Nephrology Coverage Advocacy

Program. He served as nephrology advisor to the American

Medical Association’s Relative Value Scale Update and founded

the New Mexico Renal Disease Collaborative Group.

TERRY KETCHERSID, MD, MBA

Senior Vice President and Chief Medical Officer, Fresenius Medical Care Integrated Care Group

Dr. Terry Ketchersid has clinical oversight over Fresenius

Medical Care North America’s Integrated Care Group, leading

value-based care initiatives and ESCO programs. He received his

B.A. in chemistry from Austin College, his executive MBA from

Duke University’s Fuqua School of Business and his M.D. degree

from the University of Texas Southwestern Medical School.

DINESH CHATOTH, MD

Associate Chief Medical Officer, Fresenius Kidney Care

In his role as Associate Chief Medical Officer for Fresenius

Kidney Care, Dr. Dinesh Chatoth is currently supporting the

evolution of Home Therapies for Fresenius Medical Care

North America’s dialysis services division. As medical director

for a Fresenius Kidney Care hemodialysis unit in Lawrenceville,

GA, Dr. Chatoth is former Chairman of Fresenius Medical Care

North America’s East Medical Advisory Board, and is a member

of the Fresenius Medical Care North America Corporate Medical

Advisory Board and the Fresenius Physician Technology Group.

He is President and CEO of Georgia Nephrology in Atlanta and

lectures extensively on chronic kidney disease management.

LORIEN DALRYMPLE, MD, MPH

Vice President of Epidemiology and Research, Fresenius Medical Care North America

Dr. Lorien Dalrymple serves as Vice President of Epidemiology

and Research for Fresenius Medical Care North America. Board

certified in nephrology, Dr. Dalrymple received her Bachelor of

Science in Psychology from Duke University, Medical Degree

from the University of Colorado and her Master of Public Health

from the University of Washington. Prior to joining Fresenius

Medical Care North America she was an Associate Professor of

Medicine at the University of California Davis and is a member

of the National Quality Forum Renal Standing Committee.

KURT MUSSINA, MBA

General Manager, Frenova Renal Research, Vice President Fresenius Medical Care North America Clinic Studies Operations

Chemist, executive and entrepreneur, Kurt Mussina is Vice

President of Fresenius Medical Care North America’s Clinical

Studies Operations and General Manager of Frenova Renal

Research, Fresenius Medical Care North America’s contract

clinical research division, a world-class network of more than

450 principal investigators across 260 research sites. A former

analytical chemist and Research & Development scientist for

Teva and Novartis Pharmaceuticals, he holds his Bachelor

of Science in chemistry from Montclair State University and

graduated with his Master of Business Administration from

the Fuqua School of Business at Duke University.

LEN USVYAT, PHD

Vice President, Integrated Care Analytics, Fresenius Medical Care North America

Dr. Len Usvyat chairs Fresenius Medical Care North America’s

Predictive Analytics Steering Committee and works closely

with the MONitoring Dialysis Outcomes (MONDO) initiative, an

international consortium of dialysis providers. His team provides

analytical support for the company’s dialysis clinics, pharmacy,

vascular care centers, urgent care centers, hospitalist group,

health plan and Medical Office research. He is a graduate of the

University of Pennsylvania and holds his PhD from the University

of Maastricht in the Netherlands.

AHMAD SHARIF, MD, MPH

Chief Medical Information Officer, Fresenius Medical Care North America

Dr. Ahmad Sharif is Senior Vice President and Chief Medical

Information Officer at Fresenius Medical Care North America.

Dr. Sharif has extensive experience in health information

technology, consulting with over 25 health systems across the

country and abroad, implementing and optimizing electronic

health records, clinical practice management and technology

solutions for multi-facility large academic institutions and

smaller community and critical access hospitals.

PETER KOTANKO, MD, FASN

Research Director, Renal Research Institute, Fresenius Medical Care Renal Therapies Group

Noted researcher and scholar, Dr. Peter Kotanko is Research

Director for the Renal Research Institute, heading research

initiatives to improve patient outcomes and quality of life. As

adjunct professor of medicine and nephrology at the Icahn

School of Medicine at Mount Sinai in New York City, he has

authored and co-authored more than 200 research papers

and book chapters and is the former Vice Chair of Austria’s

Hospital Barmherzige Brüder.

DUGAN MADDUX, MD, FACP

Vice President, Kidney Disease Initiatives, Fresenius Medical Care North America

Dr.Dugan Maddux champions Fresenius Medical Care North

America’s clinical innovation endeavors across the continent,

and is co-founder of the Gamewood companies, including

Acumen Physician Solutions. Blogger, writer and essayist, she

developed the Nephrology Oral History project chronicling

early dialysis pioneers and holds her Bachelor of Science

degree in chemistry from Vanderbilt University and her

Medical Doctor degree from the University of North Carolina

at Chapel Hill.

FOR MORE INFORMATION

To request on-site media interviews with Fresenius Medical Care North America experts, or for more information, please contact:

Brad Puffer Director of Public Relations Fresenius Medical Care North America (781) 460-4820 mobile brad.puffer@fmc-na.com

© 2018, Fresenius Medical Care North America, All Rights Reserved.

Our Family of Companies:ACUMEN PHYSICIAN SOLUTIONS

We develop and deliver intuitive software

tools to assist nephrologists in the practice of

medicine. We work with practices of all sizes and

with nephrologists to better streamline their

processes and meet their needs.

AZURA VASCULAR CARE

We are reshaping vascular care through our

network of outpatient vascular centers and

ambulatory surgical centers, specializing in

minimally invasive techniques to treat and

manage a wide range of vascular conditions.

FRENOVA RENAL RESEARCH

We are the world’s only contract clinical research

services provider dedicated exclusively to

improving the lives of people living with renal

disease, based on our intimate understanding of

patients affected by kidney disease.

FRESENIUS HEALTH PARTNERS

Through three distinct value-based programs, we

monitor and manage the total care of individuals

with kidney disease. Our unique, high-touch

approach helps renal patients to live life to the

fullest while managing the rising costs of care.

FRESENIUS KIDNEY CARE

We are nurses, dietitians, patient care

technicians, social workers, financial

coordinators, travel service agents and

biomedical technicians working together with

nephrologists to help improve the lives of nearly

200,000 people with kidney disease.

FRESENIUSRX

We are changing the practice of pharmacy from

simply dispensing medications to playing an

integral role in a patient’s coordinated care team,

working with patients and providers to improve

access and adherence to medication.

NATIONAL CARDIOVASCULAR PARTNERS

We are the largest outpatient cardiovascular

company in the US with a mission to provide

superior quality healthcare services that patients

would recommend, physicians prefer for their

patients and employees take pride in.

PHYSICIAN PRACTICE SERVICES

From practice management services to physician

recruitment, we provide differentiated, best-in-

class practice growth and management services

and a variety of technology solutions to help

nephrology practices grow and prosper.

RENAL RESEARCH INSTITUTE

Our highly developed and specialized expertise in

computational biomedicine, exploratory clinical

and biomedical research and data analytics

uniquely enables us to create maximum value

for Fresenius Medical Care and our patients.

RENAL THERAPIES GROUP

Our Renal Technologies and Renal

Pharmaceuticals divisions deliver hemodialysis

and peritoneal dialysis equipment, ancillary

products and renal pharmaceuticals to the

CKD community in both the clinical and

home environments.

MEDSPRING URGENT CARE

Our qualified, friendly healthcare teams offer

urgent care and occupational health services for

adults and children. We strive to be a quick and

efficient walk-in medical clinic, while providing

exceptional medical care and service.

SPECTRA LABORATORIES

We are the leading provider of renal-specific

laboratory services, using state-of-the-art

analytical equipment, automated specimen

processing and reporting applications to provide

rapid and reliable test results.

© 2018, Fresenius Medical Care North America, All Rights Reserved.

920 Winter Street Waltham, MA 02451

781–699–9000 main

800–662–1237 toll-free

fmcna.com